230 related articles for article (PubMed ID: 8735789)
21. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
22. Regimens of factor VIII administration--continuous infusion vs. bolus.
Berntorp E
Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
[TBL] [Abstract][Full Text] [Related]
23. Vascular access in hemophilia.
Powell TW; Blumoff RL; Mandel SR
Am Surg; 1981 Sep; 47(9):408-9. PubMed ID: 6792959
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of factor VIII in hemophilia A patients assessed by frequency response method.
Durisová M; Dedík L; Bátorová A; Sakalová A; Hedera J
Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):217-26. PubMed ID: 9646284
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic infusion regimens in the management of hemophilia.
Ljung RC
Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis in haemophilic children.
Liesner RJ
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
[TBL] [Abstract][Full Text] [Related]
27. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.
Martinowitz U; Schulman S; Gitel S; Horozowski H; Heim M; Varon D
Br J Haematol; 1992 Dec; 82(4):729-34. PubMed ID: 1482660
[TBL] [Abstract][Full Text] [Related]
28. Hemostasis: a practical review of conservative and operative care.
Shopnick RI; Brettler DB
Clin Orthop Relat Res; 1996 Jul; (328):34-8. PubMed ID: 8653974
[TBL] [Abstract][Full Text] [Related]
29. Continuous infusion of monoclonal antibody-purified factor VIII.
Weinstein RE; Bona RD; Rickles FR
Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966
[TBL] [Abstract][Full Text] [Related]
30. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
31. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
32. Present possibilities of surgical operations in patients with hemophilia A.
Ziemski JM
Pol Med J; 1971; 10(5):1279-82. PubMed ID: 5133677
[No Abstract] [Full Text] [Related]
33. Continuous infusion of von Willebrand factor and factor VIII after elective heart surgery in a 12-year-old girl with von Willebrand disease type 3.
Kühne T; Imbach P; Marbet GA; Caliezi C; Devay J
Pediatr Hematol Oncol; 1999; 16(6):551-6. PubMed ID: 10599096
[TBL] [Abstract][Full Text] [Related]
34. Experience gained in 35 operations in patients with hemophilia A.
Ziemski JM; Lopaciuk S; Rudowski W
Pol Med J; 1971; 10(5):1269-77. PubMed ID: 5133676
[No Abstract] [Full Text] [Related]
35. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
36. Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.
Bennett B; Ratnoff OD
J Clin Invest; 1972 Oct; 51(10):2593-6. PubMed ID: 4626847
[TBL] [Abstract][Full Text] [Related]
37. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
[TBL] [Abstract][Full Text] [Related]
38. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
Hsu HC; Chen YF; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
40. Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous infusion of Novoseven.
Ménart C; Cognet V; Petit PY; Massignon D; Négrier C
Blood Coagul Fibrinolysis; 1998 Apr; 9(3):289-90. PubMed ID: 9663714
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
